Bayer's $66 Billion Monsanto Deal and the Roundup Reckoning

The largest all-cash check ever written

On September 14, 2016, Bayer AG agreed to buy Monsanto for $128.00 a share in cash. The two companies put the transaction at roughly $66 billion including debt, and no acquirer had ever committed to pay that much without offering a single share of its own stock as currency. Werner Baumann, five months into the chief executive's job at a 153-year-old German life sciences company, had bought the most politically radioactive brand in world agriculture and had agreed to pay for all of it in cash.

The strategic logic was not exotic. Bayer sold crop chemicals and had almost no seeds business; Monsanto sold seeds and biotech traits and had one blockbuster chemical, the glyphosate herbicide Roundup. Put together, the combination would sell a farmer the seed, the trait engineered into it, the herbicide that seed tolerates, and the software that tells the farmer when to plant. Three of Bayer's competitors were merging around the same idea at the same time, which is why the deal felt, in 2016, less like an adventure than like a seat being taken before the music stopped.

What the price did not include

The number that would eventually define the transaction was not on the term sheet. In March 2015, eighteen months before Bayer signed, the World Health Organization's cancer agency had classified glyphosate as probably carcinogenic to humans, a finding the US Environmental Protection Agency rejected then and rejects now. By the time the deal closed on June 7, 2018, several thousand Americans with non-Hodgkin lymphoma had sued Monsanto over Roundup. Nine weeks later a San Francisco jury returned a verdict of $289 million against the company Bayer had just bought.

What followed is the reason this deal is studied. Roughly 170,000 claims were eventually filed. Bayer has paid out more than $10 billion, proposed a further $7.25 billion class settlement, absorbed a shareholder no-confidence vote unprecedented for a German blue chip, changed chief executives, cut its dividend by more than 95%, and watched its market value fall by roughly $60 billion, close to the entire purchase price of Monsanto. This study follows the deal from the bidding contest through the financing and the antitrust remedy into the courtroom, and asks the only question that still matters about it: whether the price was wrong, or whether the diligence was.

Monsanto started the scramble and then lost it

The wave that produced Bayer-Monsanto was started by Monsanto itself. In 2015 the St. Louis company made an approach for Syngenta valued at roughly $47 billion, and Syngenta refused it. That refusal set off a chain reaction across an industry that had spent two decades as six roughly balanced players, according to Chemical & Engineering News, which tracked the sector's collapse into four.

Dow Chemical and DuPont announced their merger in December 2015. ChemChina agreed to take Syngenta, the company Monsanto could not have. That left exactly two large independents in the middle of a consolidating market, Bayer's crop science arm and Monsanto, staring at each other. Bayer's approach in May 2016 was, in a structural sense, the last available move on the board.

Seeds and traits versus crop protection

Agriculture inputs split into two businesses that are sold to the same farmer but built on different economics. Seeds and traits is a genetics business: germplasm libraries, breeding programs, and patented biotech traits such as herbicide tolerance, licensed year after year. Crop protection is a chemicals business: herbicides, fungicides, and insecticides sold by volume, exposed to commodity pricing and to generic competition once patents expire. Monsanto dominated the first, Bayer was strong in the second, and the merger thesis across the whole 2015 to 2016 wave was that owning both let a company sell an integrated system rather than a product.

Why only Monsanto would do

Bayer's problem was that its crop science division was the wrong shape for where the industry was going. It had chemistry and almost no genetics, and a chemistry-only supplier in a trait-driven market ends up selling into someone else's system. Monsanto owned the corn and soybean germplasm, the Roundup Ready trait platform that made glyphosate the default herbicide on hundreds of millions of acres, and, through its Climate Corporation subsidiary, the most developed digital farming platform in the industry.

The counterargument, made at the time by investors who marked Bayer's shares down when the approach became public, was that this was consolidation logic rather than a genuine industrial thesis. Bayer was a pharmaceutical company as much as an agriculture company, and adding $66 billion of farm assets funded entirely with debt and new equity would leave it neither one thing nor the other. Baumann's answer was that Bayer was a life science group and that plant and human health belonged under one roof, a framing his own investors never fully accepted and that his successor would spend years defending against calls for a breakup.

The seller's position was stronger than it looked

Monsanto had a weak year behind it. Commodity crop prices were depressed, farm incomes were falling, and its own attempt to consolidate had failed. But Hugh Grant, Monsanto's chairman and chief executive, held one very good card: he was the last independent asset of scale, and everyone knew it. He also knew that a German acquirer of an American agricultural icon carried a regulatory problem that would take years to resolve, and that this problem was worth money.

That is the shape of the negotiation that followed. There was never a rival bidder. The escalation from $122 to $128 was not a contest between buyers; it was a seller extracting payment for certainty from a buyer with nowhere else to go.

The rejection that set the terms

Bayer put a proposal of $122.00 a share to Monsanto on May 10, 2016, and went public with it on May 23 after the approach leaked. Against Monsanto's unaffected closing price of $89.03 on May 9, that was a 37% premium and a headline value around $62 billion. Monsanto's board rejected it within a day, and the language of the rejection is the key to everything that followed.

The board called the proposal "incomplete and financially inadequate" while saying it remained open to talks, and Grant complained that it failed to address the "potential financing and regulatory execution risks," as reported by Chemical & Engineering News. Monsanto was not only saying the price was too low. It was saying that a signed deal from a German buyer that might never clear antitrust review was worth less than a signed deal that would, and it wanted to be paid for the difference in both cash and contractual protection.

The escalation ladder

Bayer raised twice more before signing, and each raise carried a structural concession alongside the price.

The July step is the informative one. Bayer added $3.00 a share, but it also announced a committed syndicated loan facility covering the entire purchase price with no financing condition attached, and put a $1.5 billion reverse termination fee on the table. In its own announcement of the raise, Bayer described the package as giving Monsanto shareholders "highly attractive, immediate and certain value." Certainty was the product being sold; the price increases were almost incidental.

Reverse termination fee

A reverse termination fee is money the buyer agrees to pay the target if the deal collapses for reasons on the buyer's side, most often a failure to obtain antitrust clearance. It is the mirror image of the break fee a target pays for walking away. In a deal with a long, uncertain regulatory path, the size of the reverse fee is the clearest available measure of who is carrying the regulatory risk, and the parties negotiate it as hard as they negotiate price. Bayer's fee rose from $1.5 billion to $2 billion between July and September 2016.

The final two moves, $127.50 on September 5 and a best and final $128.00 on September 7, added less than 0.4% to the price. What they bought was a signature. The merger announcement set the reverse termination fee at $2 billion, projected annual EBITDA synergies of about $1.5 billion after year three, and forecast closing by the end of 2017. Only the first of those three numbers proved accurate.

What the all-cash structure really decided

Cash consideration is usually discussed as a certainty benefit to the seller and an EPS benefit to the buyer. In this transaction it decided something far more important, and nobody said so at the time: it determined who would own the Roundup litigation.

In a stock-funded merger, Monsanto's shareholders would have rolled into the combined company and taken their share of whatever glyphosate turned out to cost. Paying $128 in cash bought them out completely at a price set before a single trial had been held. Every dollar of the liability that followed landed on Bayer's shareholders alone. This is the same allocation question that the contingent value right in Bristol-Myers Squibb's Celgene deal was built to answer, where buyer and seller genuinely disagreed about the value of a risky asset, and Bayer used no such instrument. It bought the risk outright, in cash, and did not price it.

The $57 billion bridge

An all-cash offer of that size requires the money to exist on day one, which for a European corporate means a bridge. Bayer committed a $57 billion syndicated facility co-underwritten by BofA Merrill Lynch, Credit Suisse, Goldman Sachs, HSBC and JPMorgan, and Bloomberg reported that the syndication closed in October 2016 with 27 lenders in a twelve-month deal. It was, at the time, among the largest loan commitments ever arranged for a single acquisition.

Bridge financing

A bridge loan is short-dated bank debt committed to make an acquisition fundable on signing, with the explicit expectation that it will be refinanced (taken out) with permanent capital before it matures. It exists because a seller will not accept a financing condition and the bond market cannot be tapped for a deal that may not close for two years. The bridge is expensive and carries escalating fees the longer it stays drawn, which is precisely the point: it is designed to push the borrower into the capital markets quickly.

Because clearance took almost twenty-one months, Bayer had an unusually long window to pre-fund. It used it. The equity leg came first, then the debt takeout arrived in a rush around the closing date, which is a familiar pattern in the sources and uses of funds in a large acquisition but rarely on this scale.

The table does not sum to the purchase price and was never meant to. The two equity raises came to roughly €10 billion, well short of the roughly $19 billion equity component Bayer described at signing; the balance of the bridge was refinanced in the bond markets and offset by €7.6 billion of divestiture proceeds from BASF, which the antitrust remedy obliged Bayer to collect anyway.

Rights issue

A rights issue raises equity by offering existing shareholders the right to buy new shares at a discount, in proportion to what they already own. It is the standard large-scale equity tool in Europe because it protects existing holders from dilution if they take up their rights, and it can raise sums no accelerated bookbuild could absorb. Bayer's June 2018 issue offered two new shares for every twenty-three held at €81.00 a share, raising about €6 billion net to help fund Monsanto.

The leverage the deal left behind

The financing worked, in the narrow sense that Bayer paid for Monsanto without a failed syndication or a broken covenant. What it left was a balance sheet with tens of billions of new debt, an enlarged share count, and no cushion for a liability nobody had modeled. When the litigation provisions began accumulating, Bayer had already spent its balance sheet capacity on the acquisition itself.

That is the structural reason the company's later choices were so constrained. A group with net cash can absorb an unexpected $10 billion legal bill; a group that has just levered itself to buy a $66 billion asset cannot, and must instead cut the dividend, sell assets, and eventually ask its own shareholders for authorization to issue more stock. The financing did not cause the disaster, but it removed every option for absorbing it quietly.

Master the mechanics behind a deal answer: practice 1,000+ technical questions on M&A, financing, and accretion/dilution, download our iOS app for the full toolkit.

Thirty regulators and a theory about innovation

Bayer needed clearance in roughly thirty jurisdictions, and the two that mattered took the deal apart. Neither the European Commission nor the US Department of Justice was primarily worried about prices next season. Both were worried about something harder to measure: whether reducing the number of firms capable of running a full seeds-and-chemistry research program from five to four would slow the rate at which new traits and molecules were invented at all.

The European Commission cleared the deal subject to conditions on March 21, 2018, with Margrethe Vestager saying the remedies were worth well over €6 billion and that the number of global players actively competing in seeds, pesticides and digital agriculture would stay the same. That last clause is the whole remedy philosophy in one line: the regulators did not try to stop the merger, they tried to manufacture a replacement competitor out of the pieces.

Consent decree

A consent decree is a court-enforced settlement between an antitrust authority and merging parties that permits a transaction to close on agreed conditions, usually the sale of overlapping businesses to an approved buyer. Unlike an informal undertaking, it is enforceable by the court, and violating it exposes the parties to contempt proceedings. US merger remedies of any size are almost always structured this way, and the decree names the divestiture buyer, the assets, and the deadline.

The $9 billion package that made BASF a seeds company

The US remedy went further than Europe's. On May 29, 2018 the Department of Justice announced a settlement requiring Bayer to divest businesses and assets worth about $9 billion, which Assistant Attorney General Makan Delrahim described as the largest merger divestiture the United States had ever required.

The buyer was BASF, the one large agrochemical group that had stayed out of the merger wave and could therefore be trusted to run the assets as a genuine rival. BASF agreed to pay €5.9 billion in October 2017 for Bayer's global cotton, canola and soybean seed businesses and its glufosinate herbicide business, then a further €1.7 billion in April 2018 for vegetable seeds, seed treatment, the hybrid wheat research platform and the xarvio digital farming business, a combined €7.6 billion.

What makes the decree analytically interesting is how far past the overlaps it reached. As Davis Polk noted in an analysis of the settlement, the package ran to nearly 14% of total deal value and roughly $2 billion more than Europe demanded, it forced the sale of wheat research where the parties had no US overlap, it swept in Bayer's nascent digital agriculture business, and it made BASF an actual party to the decree with the right to identify further assets it needed within a year of closing. The DOJ was not curing an overlap. It was assembling a fifth competitor from parts and giving that competitor a claim against the seller.

The remedy worked, and it did not matter

Judged against its own objective, the intervention was a success. BASF became a credible integrated player, the four-firm structure held, and no serious analyst argues that the Bayer-Monsanto merger produced the competitive harm the regulators feared. The antitrust and regulatory approval process did exactly what it is designed to do.

It also consumed twenty-one months, cost Bayer roughly $9 billion of assets at book prices set before the litigation began, and delivered the company a target that was materially more dangerous on the day of closing than on the day of signing. The regulators were scrutinizing market shares in canola seed while the risk that would destroy the transaction was accumulating, case by case, in California state court.

Dewayne Johnson resets the price of glyphosate

Bayer closed on June 7, 2018. On August 10, a San Francisco jury found for Dewayne Johnson, a school groundskeeper with terminal non-Hodgkin lymphoma who had sprayed Roundup for years, and awarded $39.25 million in compensatory damages and $250 million in punitive damages. Bayer's shares fell more than 10% on the first trading day after the verdict, and the case was the first of what were then reported as roughly 5,000 similar claims.

Punitive damages

Punitive damages are awarded not to compensate a plaintiff for loss but to punish a defendant's conduct and deter repetition. They are available in most US states on a showing of malice, fraud or conscious disregard for safety, and they are what turns a personal injury case into an existential corporate risk: compensatory damages are bounded by the plaintiff's actual injury, punitive damages are bounded only by what a jury thinks the conduct deserves and what appellate courts will tolerate. In Johnson, they were roughly six times the compensatory award.

The trial judge later cut the punitive award, and Johnson accepted a reduced judgment of about $78 million in November 2018, as CNN reported. A California appellate court cut it again in July 2020, to $20.5 million, and the California Supreme Court refused to review it that October. The number fell by 93%. The finding of liability did not move at all, and that asymmetry became the pattern.

Hardeman and Pilliod: the verdicts that would not break

Two more bellwether trials followed within nine months, one federal and one state, and both went the same way.

The three juries awarded a combined $2.42 billion and the courts let stand about $132 million, a reduction of roughly 95%. Read one way that is a story of appellate discipline restoring proportion. Read the other way, which is how the plaintiffs' bar read it, three separate juries in two court systems heard Monsanto's science defense and rejected it, and every reviewing court left liability intact while trimming only the arithmetic. For a mass tort, the second reading is the one that sets the settlement price, because a defendant that loses on liability three times out of three cannot credibly threaten to try 100,000 cases.

Bellwether trial

In mass tort litigation, thousands of similar claims are consolidated and a handful of representative cases are tried first as bellwethers. Nobody expects to try them all; the bellwethers exist to price the rest. Their verdicts tell both sides what juries do with the evidence, and settlement values for the entire inventory are then negotiated off those results. Three defense losses in the first three bellwethers is close to the worst possible outcome for a defendant, because it removes the argument that the early results were outliers.

The claim curve

The Johnson verdict did not merely cost Bayer money; it advertised the litigation. Claim counts moved from roughly 5,000 at the time of the verdict to 42,700 by October 2019 and to about 125,000 filed and unfiled claims by mid-2020. By 2026 the cumulative total was reported at around 170,000.

IARC's 2A against the EPA's "not likely"

The scientific record on glyphosate was, and remains, genuinely divided, which is why the litigation could not be resolved by pointing at a regulator. In March 2015 the International Agency for Research on Cancer classified glyphosate as probably carcinogenic to humans, its Group 2A category. The US Environmental Protection Agency reached the opposite conclusion, holding in its 2020 interim registration review decision that glyphosate is not likely to be carcinogenic to humans.

Bayer's public position through the acquisition and after it was that the EPA was right, that glyphosate had been reviewed by regulators worldwide for four decades, and that the litigation was therefore a US legal phenomenon rather than a scientific one. That position was not unreasonable. It was also, as a diligence assumption, an unhedged bet that American juries would defer to an American regulator.

Why the regulator's blessing did not stop a jury

They did not defer, for two connected reasons. The first was evidentiary: internal Monsanto documents produced in discovery, widely reported as the Monsanto Papers, gave plaintiffs' counsel material about the company's engagement with published science and with regulators that juries found more persuasive than the regulatory record itself. Liability in these cases turned less on whether glyphosate causes cancer than on how Monsanto had behaved.

The second reason was legal, and it took years to resolve. Monsanto's central defense was that federal pesticide law preempted state failure-to-warn claims, because the EPA had approved a label with no cancer warning. The Ninth Circuit rejected that defense in Hardeman, and in June 2022 the Supreme Court declined to hear the appeal, leaving the $25.2 million judgment standing.

FIFRA preemption

The Federal Insecticide, Fungicide, and Rodenticide Act gives the EPA authority over pesticide labeling and bars states from imposing labeling requirements "in addition to or different from" the federal ones. A manufacturer sued under state law for failing to warn about a risk the EPA did not require it to disclose can argue that the state claim is expressly preempted, because complying would mean changing a federally approved label. Whether that argument works has been the central legal question in the Roundup litigation for a decade.

Four days before the Hardeman cert denial, the same court of appeals vacated the EPA's human health finding on glyphosate, holding the agency had not followed its own carcinogen assessment guidelines. The EPA subsequently withdrew the interim decision. For the four years that followed, Bayer was defending a product whose safety finding had been struck down and whose preemption defense the Supreme Court had refused to hear, in front of juries that had already found against it three times.

Go deeper before an interview: our 160-page PDF covers deal frameworks, technicals, and behavioral prep end to end, access the IB Interview Guide and pair it with these case studies.

The June 2020 architecture

By 2020 Bayer had concluded it could not try its way out, and on June 24 it announced a settlement framework of $10.1 billion to $10.9 billion: between $8.8 billion and $9.6 billion to resolve current claims, including an allowance for unresolved cases, and a separate $1.25 billion to fund a class agreement covering people who might be diagnosed in the future. Bayer said the package addressed roughly 75% of about 125,000 filed and unfiled claims.

The two halves solved different problems. The first half was ordinary inventory settlement, expensive but mechanical. The second half was the one that mattered strategically, because a company cannot value a business whose liability keeps being created by future diagnoses. Bayer proposed to fix that by having a science panel determine, once, whether glyphosate causes non-Hodgkin lymphoma, and to bind future claimants to the answer.

The judge who would not sign

Judge Vince Chhabria, who supervised the federal Roundup litigation, refused. In July 2020 he told the parties he was skeptical of the future-claims class and questioned the constitutionality of moving causation from juries to a standing panel of scientists.

Bayer withdrew the class portion within days. The consequence was that the most expensive settlement in the history of agricultural products bought closure on the past and nothing on the future, which is why the litigation not only continued after 2020 but grew. The company had spent roughly $10 billion and still owned an open-ended liability, and from that point its strategy shifted from settling claims to attacking the legal theory that produced them.

A 55.5% vote of no confidence

The shareholder response arrived before the settlements did. At Bayer's annual general meeting on April 26, 2019, 55.5% of votes were cast against discharging the board of management for the prior year, down from about 97% support twelve months earlier. As Bloomberg reported, Baumann became the first chief executive of a DAX-listed company to lose such a vote.

Discharge of the management board

Under German corporate law, shareholders at the annual general meeting vote on whether to formally approve, or discharge, the conduct of the management and supervisory boards for the preceding year. The vote does not remove anyone and carries no direct legal consequence; its force is entirely reputational. A majority against is so rare among large German companies that it functions as a public censure, and it is the closest thing German governance offers to a vote of no confidence.

The vote was strange in one respect that is often missed: many investors who voted against management said they did not want it removed, because a leadership vacuum in the middle of a mass tort would make matters worse. The message was not "resign," it was "you did not know what you bought."

The diligence allegation

That charge became a lawsuit. Pension funds sued Bayer in the Northern District of California alleging that its executives had misstated the thoroughness of their pre-merger work on Roundup exposure. In October 2021 Chief Judge Richard Seeborg allowed the case to proceed, reciting the plaintiffs' allegation that Bayer had not reviewed any internal Monsanto documents and had accepted Monsanto's characterization of the litigation risks at face value.

Those allegations were never tested at trial. The case settled for $38 million, with final approval granted on October 30, 2025. But the specific claim is the one worth holding onto, because it describes a failure that is unusual in large-cap M&A: not a misjudgment of a known risk, but a decision to rely on the seller's own account of the risk in a hostile-adjacent process where the seller had every reason to minimize it. A standard due diligence process treats the target's characterization of pending litigation as a starting point for document review, not a substitute for it.

Baumann out, Anderson in, and a dividend of eleven cents

Baumann retired at the end of May 2023 and Bill Anderson, previously head of Roche's pharmaceuticals division, took over on June 1. Anderson's response was structural rather than portfolio-based: a new operating model called Dynamic Shared Ownership that stripped out layers of management, and a decision to cut the dividend for the 2023 financial year to €0.11 a share from €2.40 for 2022, a reduction of more than 95%, in order to protect the balance sheet.

The accounting caught up in parallel. Bayer took a goodwill impairment of roughly €2.5 billion in the crop business in 2023 on deteriorating glyphosate market conditions, and a further €3.27 billion goodwill impairment in the third quarter of 2024. In March 2025 the company asked shareholders to authorize new shares equivalent to 35% of its share capital as contingency funding for the litigation, and Fortune reported the stock fell more than 10% on the news, alongside a €2.6 billion net loss for 2024. By May 2025 the Wall Street Journal had reported that Bayer was preparing a bankruptcy filing for its Monsanto subsidiary as a contingency if a settlement could not be reached.

$7.25 billion and a twenty-one year claims program

On February 17, 2026, Monsanto proposed a nationwide class settlement in Missouri state court of $7.25 billion to resolve current and future non-Hodgkin lymphoma claims, funded through annual payments over roughly two decades and covering people exposed before that date who are diagnosed within the following sixteen years. The 22nd Judicial Circuit Court granted preliminary approval on March 4, 2026, and set an opt-out deadline of June 4.

It was, in substance, the second attempt at the structure Judge Chhabria had refused in 2020, moved to a friendlier forum and paired with a much larger fund. Plaintiff-side critics argued that the per-claimant amounts, reported in ranges from roughly $10,000 to $165,000 depending on severity and exposure, were far below what individual trials had produced.

Durnell and the ruling that changed the arithmetic

Then the legal theory Bayer had been attacking for eight years gave way. The Supreme Court granted certiorari in Monsanto v. Durnell on January 16, 2026, and on June 25, 2026 held 7 to 2, in an opinion by Justice Kavanaugh, that federal pesticide law expressly preempts state failure-to-warn claims where the EPA has determined that no cancer warning is required. The $1.25 million verdict below was reversed. Bayer's shares rose by as much as 19%, their largest one-day move in more than two decades.

The rescheduling is the tell. The Missouri court moved the final approval hearing to September 14, 2026 in part because claimants who had opted out to sue individually now wanted back in, their individual cases having become far less valuable overnight.

Why roughly 65,000 claims are still alive

Durnell removed a theory, not the litigation. Failure to warn was the dominant claim but never the only one, and design defect and negligence theories that do not depend on what the label said survive the ruling untouched.

Roughly 65,000 suits remained pending after the decision. Bill Anderson told investors in August 2026 that the previous ninety days had been decisive in the company's effort to contain the uncertainty, and that he looked forward to "spending less time on litigation and more time driving our performance forward." Whether he gets to depends on a hearing in a St. Louis courtroom and on what plaintiffs' counsel can do with the theories the Supreme Court left standing.

The ledger

The scale of the destruction is not seriously contested; only its cause is.

Note that Bayer's own closing announcement in June 2018 valued the transaction at $63 billion including debt, below the $66 billion quoted at signing in 2016. The ledger is not a sum; it is a set of independent measures, and the striking one is the fifth. Bayer lost, in market value, approximately what the entire acquisition cost, which is what produces the standard claim that the deal ranks among the worst in corporate history.

The business Bayer actually owns

The uncomfortable complication for that verdict is that the asset itself is not bad. Crop Science recorded sales of €21.6 billion in 2025 with growth led by corn seed and traits, according to Bayer's own annual report, and the corn and soybean germplasm and trait platforms Bayer bought remain the strongest in the industry. The glyphosate chemical business has been badly damaged by generic Chinese supply and price collapse, but glyphosate was never the point of the acquisition; the seeds and traits were.

That distinction matters for judging the deal, because it separates two failures that are usually collapsed into one. Bayer did not buy a declining business and overpay for it, the classic megadeal error visible in a case like the AOL and Time Warner merger. It bought a good business and attached to it an unbounded legal liability that arrived through a product line the strategy barely depended on.

What the diligence failure actually was

The defense of Bayer's management, which has real force, is that no reasonable acquirer in 2016 could have forecast this. The EPA said glyphosate was safe. Regulators in Europe, Japan, Australia and Canada agreed. The pending caseload was in the low thousands, tiny for a product used on hundreds of millions of acres. A first-trial loss producing $289 million, three straight bellwether defeats, and a claim count that reached six figures were not the base case on any defensible model.

The prosecution case is narrower and harder to answer. It is not that Bayer failed to predict the verdicts; it is that Bayer, on the plaintiffs' account in the securities litigation, did not read the file. IARC had classified glyphosate as a probable carcinogen eighteen months before signing. The claims were already being filed. The internal documents that would eventually persuade three juries already existed inside Monsanto and were discoverable. An acquirer that reviewed them might still have proceeded, but it would have priced differently, or insisted on a structure that shared the outcome, or at minimum not paid all cash and thereby handed the sellers a complete escape from a risk they understood better than the buyer did.

That is the specific, transferable failure, and it is a structuring failure as much as an investigative one. Cross-border acquirers routinely underweight US tort exposure because it has no analogue in their home systems, a well-documented hazard in cross-border M&A, and the standard answer when a liability is genuinely unquantifiable is not to research harder but to refuse to own it outright: an escrow, an indemnity, a stock component, a contingent structure, anything that leaves the seller with skin in the outcome. Bayer used none of them.

The verdict

On the evidence available in 2026, three things are settled. Bayer paid a full price, close to a 44% premium and about $66 billion, for an asset it had no realistic alternative to buying. It executed the transaction competently in every technical respect, financing a record all-cash deal and clearing the largest merger divestiture in US history without ever paying the $2 billion reverse termination fee. And it destroyed roughly the entire purchase price in shareholder value through a liability it did not price.

What remains genuinely contested is whether that liability was foreseeable, and here the honest answer is that the two sides are arguing about different things. Nobody could have forecast the verdicts. Someone should have read the documents. The Supreme Court's decision in Durnell has now removed the theory that generated most of the claims, and if the Missouri class settlement is approved, Bayer will have capped an exposure that was open-ended for eight years, which means the final cost of this deal is still being written. On any measure of value destroyed relative to price paid, it belongs in the small group of transactions regularly named the worst of the modern era. On the narrower question of what went wrong, it is not a story about paying too much. It is a story about buying, in cash and without protection, a risk the buyer had chosen not to look at.

1. 1"Bayer and Monsanto to Create a Global Leader in Agriculture," September 14, 2016, Bayer Crop Science.
2. 2"Bayer Increases Monsanto Offer and Provides Certainty on Financing and Regulatory Matters," July 14, 2016, PR Newswire.
3. 3"Monsanto rejects a takeover bid from Bayer," May 2016, Chemical & Engineering News.
4. 4"Four ag giants to rule them all," Chemical & Engineering News.
5. 5"Bayer Said to Close Monsanto Bridge-Loan Syndication," October 11, 2016, Bloomberg.
6. 6"Mergers: Commission clears Bayer's acquisition of Monsanto, subject to conditions," March 21, 2018, European Commission.
7. 7"Monsanto-Bayer Hurdle Merger Challenge With Divestment," May 2018, Courthouse News Service.
8. 8"Davis Polk Discusses Largest U.S. Antitrust Divestiture in Bayer-Monsanto Deal," June 13, 2018, CLS Blue Sky Blog.
9. 9"BASF signs agreement to acquire significant parts of Bayer's seed and non-selective herbicide businesses," October 13, 2017, BASF.
10. 10"BASF signs agreement to acquire additional seeds and crop protection businesses and assets from Bayer," April 2018, BASF.
11. 11"Monsanto trial: Dewayne Johnson accepts a lower award," November 1, 2018, CNN.
12. 12"Supreme Court won't derail landmark Roundup cancer verdict," June 21, 2022, E&E News by Politico.
13. 13Opinion of June 17, 2022 vacating the EPA's human health determination on glyphosate, No. 20-70787, US Court of Appeals for the Ninth Circuit.
14. 14"Judge Inclined to Deny Part of Bayer Roundup Settlement on Future Claims," July 7, 2020, Insurance Journal.
15. 15"Bayer CEO Loses Confidence Vote on Monsanto," April 26, 2019, Bloomberg.
16. 16"Pension Funds Allowed to Sue Bayer Over Due Diligence in Monsanto Acquisition," October 20, 2021, DTN Progressive Farmer.
17. 17"Bayer shares plunge as ongoing U.S. lawsuits trigger cash-raising plans," March 7, 2025, Fortune.
18. 18"Supreme Court limits Roundup cancer suits against Bayer's Monsanto," June 25, 2026, CNBC.
19. 19"Bayer's Supreme Court Win in Roundup Case No Silver Bullet," June 29, 2026, Claims Journal.
20. 20"Crop Science," Bayer Annual Report 2025, Bayer.